DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Oxaliplatin, a platinum (Pt) drug with a diaminocyclohexane (DACH) ligand, is approved for colon cancer treatment.
• Its mechanism differs from cisplatin and carboplatin.
• Novel platinum-based anticancer agents can be designed with a dual mechanism of action.

Purpose of the Study:

• To investigate the potential of a novel dual mechanism of anticancer action in demethylcantharidin (DMC)-integrated platinum complexes.
• To assess the DNA-damaging ability of these novel complexes in colorectal cancer cells.

Main Methods:

• Synthesized and studied demethylcantharidin-integrated Pt complexes: Pt(R,R-DACH)(DMC) and Pt(NH(3))(2)(DMC).
• Utilized an alkaline comet assay to evaluate DNA damage induction in HCT116 colorectal cancer cells.
• Compared DNA damage caused by novel complexes with oxaliplatin and carboplatin.

Main Results:

• The DMC ligand released from novel complexes induced additional DNA lesions compared to oxaliplatin and carboplatin.
• The DNA-damaging profile of cisplatin was observed to be characteristically different.
• This study is the first to demonstrate DMC's ability to induce DNA lesions.

Conclusions:

• Demethylcantharidin-integrated Pt complexes exhibit a dual mechanism of action, combining platinum's DNA-alkylation with DMC-induced DNA lesions.
• The novel DMC-integrated complexes demonstrate superior antiproliferative effects.
• This provides evidence for a new class of platinum-based anticancer agents.